Get the Stockscreener App
0.37
3.70%
-0.0142
Medicus Pharma Ltd stock is traded at $0.37, with a volume of 1.03M.
It is down -3.70% in the last 24 hours and down -13.00% over the past month.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
See More
Previous Close:
$0.3842
Open:
$0.3906
24h Volume:
1.03M
Relative Volume:
0.54
Market Cap:
$20.96M
Revenue:
-
Net Income/Loss:
$-28.53M
P/E Ratio:
-0.2078
EPS:
-1.7805
Net Cash Flow:
$-20.10M
1W Performance:
-1.54%
1M Performance:
-13.00%
6M Performance:
-72.99%
1Y Performance:
-87.75%
1-Day Range:
$0.37
$0.4174
1-Week Range:
$0.3504
$0.4174
52-Week Range:
$0.25
$3.06
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.37 | 20.96M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,196.03 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 634.77B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.36 | 458.24B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.07 | 323.72B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.01 | 294.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd Stock (MDCX) Latest News
MDCX|Medicus Pharma Ltd|Price:0.370|Chg%:-0.014 - TradingKey
ICYMI: Medicus Advances Leaner Teverelix Trial After FDA Review - MyChesCo
Medicus Pharma CEO details Teverelix progress – ICYMI - Proactive financial news
Medicus Cuts Planned Teverelix Trial Enrollment by Two-Thirds - MyChesCo
Medicus Pharma advances Phase 2 study following FDA and IRB feedback - Proactive financial news
Medicus Pharma (MDCX) Receives FDA Feedback for Clinical Study - GuruFocus
Medicus Pharma wins FDA backing for optimized Phase 2 Teverelix study in acute urinary retention - Bitget
Medicus Pharma redesigns Phase 2 trial for 126 patients - grafa.com
Medicus Pharma receives FDA feedback for optimized Phase 2 study By Investing.com - Investing.com Nigeria
Medicus Pharma receives FDA feedback for optimized Phase 2 study - Investing.com
Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention - The Manila Times
Medicus Pharma Receives Positive FDA Feedback and Central - GlobeNewswire
Medicus Pharma (MDCX) Stock Forum and Discussion - Moomoo
Medicus Pharma advances Teverelix Phase 2 study after FDA feedback, IRB approval - Proactive financial news
Medicus Pharma Expects About 126 Patients in Redesigned Teverelix Study - Stock Titan
Medicus Pharma on Bloomberg World - Independent Mail
Number of shareholders of Medicus Pharma Ltd. – NASDAQ:MDCX - TradingView
Number of shareholders of Medicus Pharma Ltd. – BOATS:MDCX - TradingView
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Medicus Pharma Ltd. (MDCX) Slips 3.5% as Stock Nears Critical Support LevelIndex Put Call - DonanımHaber
Enterprise value to revenue forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - MPNnow.com
Enterprise value to EBIT forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Price to sales forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Enterprise value to EBITDA forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
MDCX Stock Price, Quote & Chart - ChartMill
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - The Poughkeepsie Journal
MDCXMedicus Pharma Ltd Revenue Breakdown - Finviz
MDCX Q1 2026 Earnings: Wider-than-expected loss as clinical programs advanceEarnings Outlook Update - dars.gov.et
New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group - Voice of Alexandria
Medicus Pharma (MDCX) Stock Analysis Report | Financials & Insights - Benzinga España
Medicus Pharma Ltd. (MDCX) Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue Pipeline ProgressTangible Book Value - dars.gov.et
Medicus Pharma Warrants (MDCXW) Rally 4.6% as Buyers Defend SupportCall Resistance - dars.gov.et
Medicus Pharma Seeks Rare Pediatric Disease Designation for SkinJect Patch in Gorlin SyndromeRevenue Inflection Point - dars.gov.et
Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology? - Insider Monkey
Medicus Pharma Ltd Actuals & Estimates (NASDAQ:MDCX) - TradingView
Medicus Pharma Warrants (MDCXW) Surge Over 40%: Examining the Momentum Above Key SupportBullish Percent Index - dars.gov.et
MDCX Q1 2026 Earnings: Wider Than Expected Loss Reflects Pre-Revenue StageRevenue Surprise History - dars.gov.et
MDCX Forecast — Price Target — Prediction for 2027 - TradingView
Medicus Pharma (MDCX) Posts Solid Gain as Stock Nears Key Resistance at $0.47Risk Reversal - DonanımHaber
Medicus Pharma Ltd (MDCXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Medicus Pharma Ltd. (MDCX) Shows Modest Uptick Amid Consolidation at $0.46Sentiment Shift - dars.gov.et
MDCX Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue StageEarnings Season Review - DonanımHaber
Medicus Pharma Ltd Provides Updates on Skinject Phase 2B Pivotal Study and Teverelix Precision Medicine Program - marketscreener.com
Medicus Pharma to present SkinJect, Teverelix updates at BIO International 2026 - Proactive financial news
Medicus Pharma to Present Clinical and Regulatory Updates at 2026 Bio International Conference - Quiver Quantitative
Medicus brings SkinJect and Teverelix data to Bio 2026 - Stock Titan
Medicus Pharma (MDCX) Slips 7.7%, Testing Key Support at $0.40 Amid Broader Biotech PressuresWyckoff Distribution - Bölüm Sonu Canavarı
Medicus Pharma Share PriceMDCX, RNS News, Articles, Quotes, & Charts (NASDAQ:MDCX) - Proactive financial news
Medicus Pharma advances Teverelix in prostate cancerICYMI - Proactive financial news
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.88%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):